NCT00328107View on ClinicalTrials.gov

Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

459

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza Vaccine, recombinant Hemagglutinin

0.5mL dose for IM injection

Trial Locations (3)

14642

Rochester Medical Center, Rochester

22908

University of Virginia Health System, Charlottesville

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Protein Sciences Corporation

INDUSTRY

NCT00328107 - Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter